New Zealand participation in Australian synchrotron will boost medical research
This article was originally published in Clinica
New Zealand has invested Aus$5m (US$4m) in Australia's Melbourne-based synchrotron project, due to open in 2007, giving New Zealand's scientists access to a powerful research tool. Included amongst the diverse fields that synchrotron light is used are bioscience (cell biology) and medical research (diagnosing disease, high resolution imaging, cancer radiation therapy).
You may also be interested in...
The regulatory agency also urges qualified persons at drug companies to let the agency know as soon as possible if they are finding that the new measures are not flexible enough to deal with the current logistical challenges quickly.
The Swiss biotech's focal-onset seizure therapy, which is licensed from South Korea's SK and is already approved in the US, could have potential in indications beyond epilepsy, Arvelle's CEO tells Scrip.
Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.